{"id":22697,"date":"2023-01-12T14:14:26","date_gmt":"2023-01-12T13:14:26","guid":{"rendered":"https:\/\/idibell.cat\/?p=22697"},"modified":"2023-01-12T14:15:56","modified_gmt":"2023-01-12T13:15:56","slug":"la-fundacio-niemann-pick-financa-lassaig-clinic-dun-farmac-per-a-parar-el-deteriorament-cognitiu-de-la-malaltia","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2023\/01\/la-fundacio-niemann-pick-financa-lassaig-clinic-dun-farmac-per-a-parar-el-deteriorament-cognitiu-de-la-malaltia\/","title":{"rendered":"La Fundaci\u00f3 Niemann-Pick finan\u00e7a l\u2019assaig cl\u00ednic d\u2019un f\u00e0rmac per a parar el deteriorament cognitiu de la malaltia"},"content":{"rendered":"<p>Avui la Fundaci\u00f3 Niemann-Pick Espanya ha vingut a fer entrega del xec per valor de 71.056,25 euros que finan\u00e7aran \u00edntegrament un estudi pilot per determinar l&#8217;efic\u00e0cia i la seguretat del f\u00e0rmac Efavirenz per a pal\u00b7liar el deteriorament cognitiu dels pacients d&#8217;aquesta malaltia minorit\u00e0ria d&#8217;origen gen\u00e8tic i per la qual actualment no hi ha cura.<\/p>\n<p>A l&#8217;acte hi ha assistit el Dr. Gabriel Capell\u00e1, director de l&#8217;IDIBELL, la Dra. Montserrat Figuerola, gerent de l&#8217;\u00e0rea Territorial Metropolitana Sud, el Dr. Javier Tapia Mart\u00ednez, Subdirector M\u00e8dic de l&#8217;Hospital Universitari de Bellvitge (HUB), i el Dr. Jordi Gasc\u00f3n, investigador principal del grup de recerca en Malalties Neurol\u00f2giques i Neurogen\u00e8tica de l&#8217;IDIBELL i cap de secci\u00f3 del Servei de Neurologia del HUB, qui liderar\u00e0 l&#8217;estudi. El Dr. Gasc\u00f3n ha agra\u00eft l&#8217;esfor\u00e7 i el comprom\u00eds de l&#8217;associaci\u00f3 en l&#8217;impuls de la recerca com a eina per millorar la qualitat de vida dels pacients.<\/p>\n<p>La Fundaci\u00f3 Niemann-Pick Espanya est\u00e0 formada per fam\u00edlies de pacients i rep el suport de voluntaris, amics i col\u00b7laboradors. La seva tasca es divideix en tres grans pilars: l&#8217;orientaci\u00f3 familiar, la divulgaci\u00f3 i la recerca. Per aquesta \u00faltima han creat les beques Juan Gir\u00f3n que donen suport a projectes enfocats a con\u00e8ixer i buscar nous tractaments per aquesta malaltia, com el del Dr. Gasc\u00f3n.<\/p>\n<p><strong>Un antiretroviral contra el VIH per al tractament de Niemann-Pick tipus C<\/strong><\/p>\n<p>L&#8217;assaig que es finan\u00e7ar\u00e0 amb aquests diners busca determinar l&#8217;efic\u00e0cia de l&#8217;Efavirenz per a reduir els problemes d&#8217;aprenentatge i de comportament dels pacients i aix\u00ed millorar-ne la qualitat de vida. Es tracta d&#8217;un f\u00e0rmac utilitzat com antiretroviral contra el VIH que millora la funci\u00f3 d&#8217;un enzim que regula la distribuci\u00f3 del colesterol en la sinapsi, el que el converteix en un gran candidat pel Niemann-Pick.<\/p>\n<p>Fins ara els resultats en models de ratolins han estat esperan\u00e7adors, per aix\u00f2 s&#8217;inicia la recerca translacional a l\u2019IDIBELL i el HUB en 14 dels 27 pacients majors de 14 anys diagnosticats de Niemann-Pick tipus C a l&#8217;Estat.<\/p>\n<p>&nbsp;<\/p>\n<p>M\u00e9s informaci\u00f3: <a href=\"https:\/\/idibell.cat\/2022\/07\/un-antiviral-generic-podria-millorar-lesperanca-de-vida-dels-pacients-duna-malaltia-minoritaria-sense-cura\/\">Un antiviral gen\u00e8ric podria millorar l\u2019esperan\u00e7a de vida dels pacients d\u2019una malaltia minorit\u00e0ria sense cura<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avui la Fundaci\u00f3 Niemann-Pick Espanya ha vingut a fer entrega del xec per valor de 71.056,25 euros que finan\u00e7aran \u00edntegrament un estudi pilot per determinar l&#8217;efic\u00e0cia i la seguretat del f\u00e0rmac Efavirenz per a pal\u00b7liar el deteriorament cognitiu dels pacients d&#8217;aquesta malaltia minorit\u00e0ria d&#8217;origen gen\u00e8tic i per la qual actualment no hi ha cura.<\/p>\n","protected":false},"author":8,"featured_media":22698,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-22697","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar"],"publishpress_future_action":{"enabled":false,"date":"2024-11-24 12:16:33","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=22697"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22697\/revisions"}],"predecessor-version":[{"id":22700,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22697\/revisions\/22700"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22698"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=22697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=22697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=22697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}